Medical News

RSS

Artery scans detect “silent atherosclerosis” in 1 in 13 adults under 30

Researchers studying 16,808 adults aged 18 to 70 found that silent atherosclerosis was detectable in early adulthood, with plaque present in 57.1% of those who completed imaging across three arterial territories. Plaque prevalence and burden were higher in older age groups, with men showing earlier evidence of disease than women, while conventional cardiovascular risk scores identified relatively few people with existing plaque.

10 Nov 2026

The gap between male and female runners is shrinking. What's driving it?

A study of 13,094 performances by 3,611 elite runners across 11 running disciplines found that the performance gap between women and men narrowed from 13.2% in 2001 to 11.9% in 2025. Women improved approximately twice as much as men, with the greatest relative gains in middle- and long-distance races, challenging the longstanding assumption that the gap had stabilized.

10 Nov 2026

Video-assisted informed consent shortens face-to-face cancer surgery consultations

For patients undergoing gastric cancer surgery, informed consent (IC) can involve extensive information about surgical methods, complications, risks, benefits, and life after treatment.

10 Nov 2026

Targeting brain cleaning gene could help treat or prevent Alzheimer's

A gene responsible for compacting trash inside the brain appears to be a key player in Alzheimer's disease, and doctors may be able to target it to better treat or help prevent the devastating condition, new UVA Health research suggests.

10 Nov 2026

New patient-centered initiative aims to accelerate pediatric AML research and treatments

Blood Cancer United today announced the launch of Dare to Dream REALworld: AML, a patient-centered initiative co-founded with Rally Foundation for Childhood Cancer Research.

10 Nov 2026

Mayo Clinic research advances treatment options for genitourinary cancers

Cancers of the reproductive and urinary organs, known as genitourinary cancers, affect millions of people worldwide each year. Yousef Zakharia, M.D., a Mayo Clinic medical oncologist, leads clinical research aimed at improving treatment results for patients with kidney, bladder and prostate cancers.

10 Nov 2026

Awake deep brain stimulation helps personalize treatment for essential tremor

Awake deep brain stimulation (DBS) surgery can provide information beyond what imaging alone can capture, helping clinicians personalize electrode placement for patients with essential tremor, according to a Mayo Clinic study published in Operative Neurosurgery.

10 Nov 2026

Protein marker detects early Huntington's disease before brain damage

Before motor or cognitive impairments appear and before brain volume loss becomes evident, some individuals carrying the genetic mutation that causes Huntington's disease already show signs of neuronal injury.

10 Nov 2026

Subtle changes in deep sleep before Alzheimer's symptoms appear

The study identifies slow-wave sleep alterations as potential biomarkers for Alzheimer's, emphasizing their role in cognitive health and disease progression.

10 Nov 2026

Regular coffee consumption alters gut bacteria and digestive physiology

If you drink coffee regularly, it appears to alter not only your gut bacteria but also the physiology of the gut itself. That is the conclusion of a study from the University of Copenhagen, which may help point the way towards better treatments for constipation.

10 Nov 2026

Common blood pressure drugs may improve ulcerative colitis therapy

A class of blood pressure medications may improve a widely used treatment for ulcerative colitis, the most common type of inflammatory bowel disease, suggests a new study, led by Northwestern Medicine and Kiel University in Germany, of thousands of patients with the disease.

10 Nov 2026

Meeting WHO's air pollution guidelines could save nine million lives

Meeting the World Health Organization's recommended annual guidelines for air pollution resulting from fine particulate matter and nitrogen dioxide has the potential to save more than 9 million lives a year in low- and middle-income countries, say University of Cambridge researchers.

10 Nov 2026

Tobacco use independently linked to anorectal sensorimotor dysfunction and fecal incontinence

Tobacco use is independently associated with anorectal sensorimotor dysfunction and fecal incontinence, according to a recent study published ahead of print in The American Journal of Gastroenterology.

10 Nov 2026

A weight-loss drug eased knee arthritis pain in two major trials

Retatrutide effectively alleviates knee pain and enhances mobility in obese osteoarthritis patients, but long-term safety and joint health remain uncertain.

10 Nov 2026

Could a common diabetes drug help prevent long COVID?

Metformin use soon after COVID-19 infection is associated with a 53% reduction in long COVID or death risk, reinforcing previous clinical findings.

10 Nov 2026

New $46M grant allows the University of Oxford and Boston Children’s Hospital to lead Genetic Medicines Hub within ARIA ecosystem

The University of Oxford and Boston Children’s Hospital, with collaboration from The Jackson Laboratory and N=1 Collaborative, have been selected to establish a new Genetic Medicines Hub, one of six research hubs within the Aligning Research to Impact Autism (ARIA) ecosystem.

10 Nov 2026

Could Ozempic and Wegovy affect unborn babies?

They’re the blockbuster drugs transforming weight loss, helping millions of people to shed unwanted pounds.

10 Nov 2026

Lab Thread launches new AI tools and strengthens platform with universal AI assistant compatibility

Lab Thread Ltd, a UK-based life science software company, today announced the launch of a new Model Context Protocol (MCP) server that lets scientists connect their own AI assistants directly to their laboratory data.

From Lab Thread 10 Nov 2026

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

10 Nov 2026

European commission approves label expansion of Pepaxti to third-line treatment

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announced that the European Commission (EC) has formally approved the Type II variation application for Pepaxti (melflufen).

From Oncopeptides AB (publ) 10 Nov 2026